We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

100 hedge funds and large institutions have $227M invested in Rigel Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 35 increasing their positions, 30 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more call options, than puts

Call options by funds: $444K | Put options by funds: $293K

42% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 12

17% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 30

5% more funds holding

Funds holding: 95 → 100 (+5)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

24% less capital invested

Capital invested by funds: $300M → $227M (-$73.5M)

Holders
100
Holders Change
+5
Holders Change %
+5.26%
% of All Funds
2.9%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
17
Increased
35
Reduced
30
Closed
12
Calls
$444K
Puts
$293K
Net Calls
+$151K
Net Calls Change
-$421K

Top Buyers

1
VAM
Visium Asset Management
New York
+$5.9M
2
BC
Broadfin Capital
New York
+$4.08M
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.04M
4
Two Sigma Investments
Two Sigma Investments
New York
+$1.81M
5
SM
Sabby Management
Florida
+$1.66M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$16.5M
2
BI
BVF Inc
California
-$5.25M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.82M
4
PAI
Palo Alto Investors
California
-$3.18M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$3M
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$1.44M -$401K -13,678 -21%
BBA
27
Baker Bros. Advisors
New York
$1.43M – – –
TC
28
TFS Capital
Pennsylvania
$1.38M -$290K -9,893 -17%
Jacobs Levy Equity Management
29
Jacobs Levy Equity Management
New Jersey
$1.33M +$970K +33,052 +244%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$1.27M +$23.1K +788 +2%
KCM
31
Kennedy Capital Management
Missouri
$1.21M +$481K +16,397 +63%
Geode Capital Management
32
Geode Capital Management
Massachusetts
$1.2M +$13.4K +456 +1%
TCIM
33
TIAA CREF Investment Management
New York
$1.13M -$57.5K -1,960 -5%
RA
34
Royce & Associates
New York
$881K +$185K +6,299 +26%
BIM
35
BlackRock Investment Management
Delaware
$850K -$17.2K -586 -2%
AllianceBernstein
36
AllianceBernstein
Tennessee
$845K -$95.4K -3,250 -10%
Susquehanna International Group
37
Susquehanna International Group
Pennsylvania
$825K +$770K +26,230 +959%
RFC
38
Russell Frank Company
Washington
$709K +$245K +8,357 +57%
Two Sigma Advisers
39
Two Sigma Advisers
New York
$672K +$693K +23,619 New
Charles Schwab
40
Charles Schwab
California
$671K +$20.1K +684 +3%
SFM
41
Sphera Funds Management
Israel
$653K +$672K +22,910 New
CS
42
Credit Suisse
Switzerland
$631K +$359K +12,247 +124%
HVC
43
Healthcare Value Capital
New Jersey
$570K +$587K +20,000 New
Goldman Sachs
44
Goldman Sachs
New York
$527K -$465K -15,829 -46%
BG
45
BlackRock Group
United Kingdom
$474K – – –
TI
46
Turner Investments
Pennsylvania
$470K +$483K +16,457 New
ARTA
47
A.R.T. Advisors
New York
$466K +$136K +4,630 +39%
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$450K +$2.64K +90 +0.6%
Bank of America
49
Bank of America
North Carolina
$397K +$233K +7,921 +132%
MCM
50
Munder Capital Management
Michigan
$384K – – –
1
2
3 4 5

RIGL Hedge Fund Activity: Q4 2013 in Review

100 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2013, worth a combined $227M — down 24% from $300M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new RIGL positions and 12 closed out — a net gain of 5 holders — while 35 added to existing stakes and 30 trimmed.

The largest buyer was Visium Asset Management, opening a new position worth an estimated $5.9M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $16.5M sold.

  • 100 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2013, up from 95 in Q3 2013.
  • Funds reported $227M of Rigel Pharmaceuticals stock for Q4 2013, down 24% quarter-over-quarter.
  • 17 funds opened new Rigel Pharmaceuticals positions in Q4 2013 and 12 closed out, a net change of +5 holders.
  • The largest Rigel Pharmaceuticals buyer in Q4 2013 was Visium Asset Management, an estimated $5.9M added.
  • The largest Rigel Pharmaceuticals seller in Q4 2013 was T. Rowe Price Associates, an estimated $16.5M sold.

Based on aggregated 13F filings for Q4 2013.